Dr. Douglas S. Reintgen, MD

Dr. Reintgen practices at AdventHealth Tampa in Tampa, Florida, part of AdventHealth.

Dr. Reintgen's NPI, 1609869759, was assigned on August 24, 2005. Dr. Reintgen graduated from Duke University School Of Medicine in 1979. Dr. Reintgen holds Florida license ME51078.

Dr. Reintgen's primary practice is AdventHealth Tampa, at 3100 E Fletcher Ave, Tampa, FL 33613 in Hillsborough County. The practice phone is (813) 615-7200.

Dr. Reintgen's primary practice is AdventHealth Tampa in Tampa, Florida, part of AdventHealth. Dr. Reintgen is also affiliated with AdventHealth Carrollwood. The medical group on file is Tampa General Medical Group (TGMG). Dmand AI also links Dr. Reintgen to 2 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Reintgen practices, 5 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Reintgen's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dmand AI has Dr. Reintgen's licenses on file in 3 states: Florida, North Carolina and Nevada.

Dmand AI lists mastectomy among the conditions Dr. Reintgen treats.

CMS data shows 236 Medicare services from Dr. Reintgen across 3 procedure codes in 2024, for 93 Medicare patients. Medicare paid $14,001 for them.

CMS counts 93 Medicare patients who saw Dr. Reintgen in 2024. The largest group is 65 to 74, with 37 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 20% are also on Medicaid. Their average risk score is 3.15, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Reintgen's median patient age at 72, with 44% women.

In 2024, Dr. Reintgen wrote 61 Medicare Part D claims for 39 patients. 98% of them were for generic drugs. CMS names the drug for 46 of them, across 2 drugs with 11 or more claims each, at $378 in total drug cost. In 2022, CMS named 80 claims across 2 drugs.

Dr. Reintgen accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 24 procedures of removal of tissue by Dr. Reintgen, more than 71% of the clinicians it reports for that procedure.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 10 papers to Dr. Reintgen, published from 2013 to 2021. 2016 was the busiest year, with 4. The most frequent topics are Sentinel Lymph Node Biopsy, Melanoma and Lymphatic Metastasis. Dr. Reintgen has published most often in Clin Breast Cancer. Dr. Reintgen's most frequent co-authors are James W. Jakub, MD, Gray B. Swor, MD and Peter D. Beitsch, MD.

CMS Open Payments shows 202 general payments to Dr. Reintgen from 41 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 84% of the total. Merck Sharp & Dohme Corporation paid the most, $62,574. It also lists 2 research payments totaling $1,395 from 2016 to 2017.

Dr. Reintgen graduated from Duke University School Of Medicine in 1979.

Dr. Reintgen is in network with 18 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 12. Check the plan with the practice before a visit.